Colorectal surgery is concerned with diseases of the colon, rectum, and anus, such as cancer, diverticulitis, and inflammatory bowel disease. The Mater Hospital has five colorectal surgeons with a special interest in colorectal cancer, and is one of the National Rectal Cancer Centres.

Colorectal Cancer

In 2014 over 250 colon cancers were diagnosed and treated at the Mater Misericordiae University Hospital. Our surgeons are also participants in the National Colorectal Cancer Screening Programme. The vast majority of cancers identified through the national screening programme are early stage colorectal cancers.

Pseudomyxoma Peritonei & HIPEC

The Mater Hospital established a treatment programme for patients with peritoneal malignancy in 2013 and has put in place the necessary medical and surgical expertise, theatre and intensive care facilities. The first case of surgical cytoreduction with HIPEC in Ireland was successfully completed at the Mater Hospital in June 2013. Since then, over 60 cases have been successfully completed.  

Innovative Treatments

New and innovative techniques have led to the development of organ preserving strategies for patients with early stage rectal cancers. Transanal minimally invasive surgery (TAMIS or TaTME) provides a less invasive surgical option for patients with early stage cancer. Techniques such as this reduce pain and recovery time for patients. Previously, surgery to remove these tumours required an abdominal incision. Now using innovative approaches, certain early stage cancers or rectal polyps may be removed without a surgical incision.


The Mater surgeons have a significant interest in surgery for all types of hernias, including ingiunal (groin) hernias, complex incisional hernias requiring abdominal wall reconstruction, parastomal hernias, and sports hernias ("Gilmore's Groin"). Both open and laparoscopic ("keyhole") approaches are offered.

Hepato-Pancreato-Biliary (HPB) Surgery

The Hepato-Pancreato-Biliary (HPB) surgical team has specialist expertise in the management of liver, pancreatic and biliary disease. This includes treatment of both benign and malignant conditions.

The HPB team includes surgeons, diagnostic/interventional radiologists, hepatologists, gastroenterologists, oncologists, and pathologists with special interest in biliary, liver and pancreatic diseases. They use innovative techniques to provide quality care to patients including a two stage Hepatectomy procedure combined with Portal Vein Embolization for Colorectal Liver Metastases. These tumours were previously unresectable with only 10% of colorectal metastatic patients being suitable for surgery. With new advances, between 30-40% of patients are suitable for this surgical option.

Gallbladder and Biliary disease

The HPB unit is involved in the management of gallstone disease along with benign and malignant diseases of the gallbladder. Their expertise extends to management of benign and malignant diseases involving the bile duct system that drains bile from the liver to the intestine.

Pancreatic disease

Benign pancreatic diseases like cystic tumours including intraductal papillary mucinous neoplasms (IPMN) are reviewed by the team, who also have a broad experience in the management of acute and chronic pancreatitis. Following evaluation, the surgical team offers total pancreatectomy and islet auto-transplantation for a select sub-set of patients with chronic pancreatitis.